Patients Chronic kidney disease: treating a silent killer In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.
Views & Analysis AstraZeneca on expanding its diabetes research franchise AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.
News Sanofi pledges a $20 billion investment programme in the US Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.